• Earlier in March 2026, PROCEPT BioRobotics highlighted that the European Association of Urology has upgraded Aquablation therapy to a strong recommendation as a surgical option for men with benign prostatic hyperplasia, positioning it as an alternative to transurethral resection of the prostate, especially for those seeking to preserve ejaculatory function.
• This guideline upgrade, backed by multiple WATER clinical trials and growing international validation including NICE support in the UK, underscores how Aquablation and the HYDROS AI-enabled robotic system are increasingly embedded in evidence-based urologic practice.
• We’ll now explore how Aquablation’s new strong backing in European guidelines could influence PROCEPT BioRobotics’ investment narrative and growth drivers.

Find 55 companies with promising cash flow potential yet trading below their fair value.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation and HYDROS can become a standard surgical option in BPH, driving wider system placement and recurring procedure use despite ongoing losses. The EAU’s strong Aquablation recommendation directly supports the core adoption and utilization catalyst in the near term, but it does not eliminate key risks around reimbursement pressure, competition and the company’s reliance on a single technology platform.

The March 12 announcement on HYDROS’ international rollout is especially relevant here, because it links the upgraded European guidelines to a concrete commercialization path for the AI-enabled system in markets like the UK. Together, stronger guideline support and a next generation platform installed across more hospitals could reinforce the existing catalyst of procedure growth, while also amplifying exposure to risks tied to capital budgets and potential shifts of procedures away from hospital settings.

However, investors should also be aware that heightened competition and shifting BPH care into outpatient centers could still...

PROCEPT BioRobotics' narrative projects $563.8 million revenue and $70.4 million earnings by 2028.

Uncover how PROCEPT BioRobotics' forecasts yield a $32.50 fair value, a 30% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already saw room for revenue to climb toward about US$624.2 million and positive earnings, yet the EAU decision and the risk of BPH procedures moving out of hospitals highlight how differently you could view PROCEPT’s future and why it is worth weighing several viewpoints before deciding what this stock means for your portfolio.

Explore 6 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth just $30.44!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

No Opportunity In PROCEPT BioRobotics?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.